Grace Therapeutics Inc (GRCE) Q3 2024 Earnings Report

Grace Therapeutics Inc, trading as GRCE, reported a loss-making QQ3 2024 quarter with no revenue, underscoring the challenging funding runway common to early-stage biotechs. Operating loss for the quarter was -$3.704 million and net income came in at -$4.155 million, translating to -$0.36 per share on diluted basis. R&D expenditures totaled $2.194 million and general & administrative costs were $1.509 million, driving total operating expenses of $3.704 million. EBITDA declined to -$3.702 million, while totalOtherIncome/Expenses net was -$1.056 million, contributing to a pretax loss of -$4.760 million and a bottom-line loss of -$4.155 million.

The balance sheet shows Grace Therapeutics maintaining a solid liquidity position with cash and cash equivalents of $18.545 million at period-end and an overall net cash position (net debt negative by $18.521 million). However, the company carries substantial intangible assets ($41.128 million) and goodwill ($8.138 million), alongside a negative accumulated deficit (retained earnings) of approximately $207.953 million, reflecting a long history of R&D investment without commercial revenue. The company continues to operate without revenue today, and management commentary remains unavailable in the provided transcript. The pipeline centers on GTX104 for subarachnoid hemorrhage, with GTX102 and GTX101 in earlier-stage development, highlighting meaningful future catalysts but also substantial execution risk.

Near-term investors should focus on (1) the cash runway given the current quarterly burn, (2) progress and milestones on GTX104 and any potential partnerships or licensing discussions, and (3) any management guidance or updates on strategic options (financing, collaboration, or corporate actions). Given the lack of reported revenue and ongoing R&D focus, the stock remains a high-risk, high-uncertainty bet with potential upside tied to successful clinical events or favorable commercialization deals.